Immuneering Corporation has shared new data from its ongoing Phase 2a study evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first-line treatment of pancreatic cancer. The study reports a median progression-free survival (mPFS) of 9.6 months for the atebimetinib + mGnP combination in a broad patient population. By comparison, benchmark mPFS values for standard regimens are reported as 5.5 months for GnP, 6.4 months for FOLFIRINOX, and 7.4 months for NALIRIFOX. At nine months, progression-free survival probability was 53% [31, 71] for patients receiving atebimetinib + mGnP. The median follow-up for overall survival was 9.0 months as of the August 26, 2025 data cutoff. No head-to-head clinical trials have been conducted, and differences exist between trial designs and subject characteristics. You can access the full presentation through the link below.